Theratechnologies Inc. (THTX)
NASDAQ: THTX · Real-Time Price · USD
3.170
0.00 (0.00%)
Jul 28, 2025, 2:26 PM - Market open
Theratechnologies Revenue
Theratechnologies had revenue of $17.73M in the quarter ending May 31, 2025, a decrease of -19.48%. This brings the company's revenue in the last twelve months to $84.38M, up 2.19% year-over-year. In the fiscal year ending November 30, 2024, Theratechnologies had annual revenue of $85.87M with 5.02% growth.
Revenue (ttm)
$84.38M
Revenue Growth
+2.19%
P/S Ratio
1.72
Revenue / Employee
$819,204
Employees
103
Market Cap
145.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2024 | 85.87M | 4.10M | 5.02% |
Nov 30, 2023 | 81.76M | 1.71M | 2.13% |
Nov 30, 2022 | 80.06M | 10.23M | 14.66% |
Nov 30, 2021 | 69.82M | 3.77M | 5.71% |
Nov 30, 2020 | 66.05M | 2.84M | 4.49% |
Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
THTX News
- 19 days ago - Theratechnologies Reports Financial Results for the Second Quarter 2025 - GlobeNewsWire
- 24 days ago - Theratechnologies to Announce Second Quarter 2025 Financial Results - GlobeNewsWire
- 25 days ago - Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak - GlobeNewsWire
- 2 months ago - Theratechnologies Reports on its Annual Meeting of Shareholders - GlobeNewsWire
- 3 months ago - Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV - GlobeNewsWire
- 3 months ago - Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer - Seeking Alpha
- 3 months ago - Theratechnologies Provides Update on Sale Process - GlobeNewsWire
- 3 months ago - Soleus Capital Issues Letter to The Board of Theratechnologies - Business Wire